View Rule
| View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
| HHS/FDA | RIN: 0910-AH53 | Publication ID: Fall 2019 |
| Title: Medical Device De Novo Classification Process | |
|
Abstract:
De novo classification decreases regulatory burdens because manufacturers can use a less burdensome application pathway under the FD&C Act to market their devices. The rule would establish procedures and criteria for the de novo process and would make it more transparent and predictable for manufacturers. |
|
| Agency: Department of Health and Human Services(HHS) | Priority: Other Significant |
| RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Final Rule Stage |
| Major: No | Unfunded Mandates: No |
| EO 14192 Designation: Other | |
| CFR Citation: 21 CFR 860 | |
| Legal Authority: 21 U.S.C. 321(h) 21 U.S.C. 360c, 360i-360j 21 U.S.C. 371 21 U.S.C. 374 | |
|
Legal Deadline:
None |
||||||||||||
Timetable:
|
| Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
| Small Entities Affected: No | Federalism: No |
| Included in the Regulatory Plan: No | |
| RIN Data Printed in the FR: No | |
|
Agency Contact: Laurie Sternberg Regulatory Counsel Department of Health and Human Services Food and Drug Administration Suite 200N (HFM-630), 10903 New Hampshire Avenue, Building 66, Room 5517, Silver Spring, MD 20993 Phone:240 402-0425 Email: laurie.sternberg@fda.hhs.gov |
|
An official website of the United States government



